Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

AIN

33

Pipeline Programs↗

30

Active Trials↗

50

Companies Involved↗

AIN is a moderately active landscape with 33 programs across 50 companies. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

58/100

Pipeline Velocity

27/100

Mech. Concentration

8/100

Completion Rate

81/100

Attrition Rate

15/100

Pipeline

Programs by Phase

Preclinical11

Bio-Feedback Training

Kaohsiung Medical University Chung-Ho Memorial Hospital

JWH018

Maastricht University

Proparacaine Hydrochloride

Sun Yat-sen University

Sodium Benzoate

Liminal BioSciences Ltd.

Fexofenadine Hydrochloride

University Ghent

Phase 14

Cocaine IV

Embera NeuroTherapeutics, Inc.

Pentoxifylline

Validus Pharmaceuticals

Alcohol

Astellas

Ziftomenib

Kura Oncology, Inc.

Phase 215

Avapritinib

Blueprint Medicines

R-Dhaox

Sun Yat-sen University

Neomta2

Cairo University

Zanubrutinib

BeOne Medicines

Olaparib

AstraZeneca

Phase 33

Tanruprubart

Annexon, Inc.

GM-CSF

Y-mAbs Therapeutics

Galinpepimut-S

Sellas Life Sciences Group

Approved

No programs

Analysis

Modality Breakdown

93%

Small molecule

27 of 29 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 29 classified programs, each share of the total. Modality classified for 100% of 33 pipeline programs.

Analysis

Trial Status

349

clinical trials

Completed228 · 65%

Unknown status37 · 11%

Terminated34 · 10%

Withdrawn17 · 5%

Recruiting16 · 5%

Not yet recruiting8 · 2%

Other9 · 3%

Clinical Trials

Trial Activity

349 trials

Luspatercept for Clonal Cytopenias of Uncertain Significance

Recruiting·WWeill Medical College of Cornell University·Phase 2·NCT06788691·50 enrolled

A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive

Recruiting·BBeijing Pearl Biotechnology Limited Liability Company·Phase 3·NCT06930794·300 enrolled

Identifying Correlates of Brain Microglial Activation in Neuropsychiatric Syndromes: a Dimensional Approach

Recruiting·TThe University of Texas Health Science Center, Houston·Phase 1·NCT03705715·200 enrolled

"Sexual Health Assessment of TinidaZole Against M. Genitalium (SHAZAM)"

Recruiting·UUniversity of Washington·Phase 2·NCT07088419·40 enrolled

An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)

Recruiting·AAnnexon, Inc.·Phase 3·NCT07020819·30 enrolled

The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature

Recruiting·—·N/A·NCT05067998·25 enrolled

Cocaine and Pentoxifylline (BED IN 47)

Recruiting·—·Phase 1·NCT07086794·30 enrolled

Tegoprazan-containing Sequential for H. Pylori

Recruiting·SSeoul National University Bundang Hospital·N/A·NCT06382493·400 enrolled

Whole Grain Job's Tear, Muscle Health, Blood Glucose and Lipid Level

Recruiting·TTaipei Veterans General Hospital, Taiwan·Phase 2·NCT06503172·80 enrolled

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

Recruiting·—·Phase 4·NCT06958796·80 enrolled

Maintenance Venetoclax in AML Fit Patients

Recruiting·SSohag University·N/A·NCT07244367·80 enrolled

Ziftomenib Maintenance Post Allo-HCT

Recruiting·MMassachusetts General Hospital·Phase 1·NCT06440135·22 enrolled

Impulsivity Domains and Subjective Response

Recruiting·—·Phase 1·NCT05929677·250 enrolled

Autophagy Maintenance (AUTOMAIN)

Recruiting·MMedical University of South Carolina·Phase 2·NCT06971744·38 enrolled

Maintenance Zanzalintinib With Etoposide After HDCT in GCT

Recruiting·IIndiana University·Phase 1/2·NCT06937866·38 enrolled

Page 1 of 24

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)